Podcasts

Recent Episodes

August 7, 2026

Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

August 4, 2026

An Ophthalmologist Guides Oncologists and Patients Through ADC-Related Eye Toxicities: With Sara Nunnery, MD, MSCI; and Sarah Sunshine, MD

August 3, 2026

From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC

Douglas W. Sborov, MD, MS, discussed the FDA approval of isatuximab for subcutaneous injection in multiple myeloma indications.

July 31, 2026

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

Solange Peters, MD, PhD, University Hospital of Lausanne

July 31, 2026

Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

July 31, 2026

Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

July 30, 2026

Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

July 30, 2026

Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Marlana M. Orloff, MD, the Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, and associate professor at Thomas Jefferson University Hospital

July 29, 2026

Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

July 28, 2026

Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD

All series

All Podcasts

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

July 9th 2026

OncLive On Air® CE

D. Ross Camidge, MD, PhD; Funda Meric-Bernstam, MD, department chair, Endowed Nellie B. Connally Chair in Breast Cancer, Department of Investigational Cancer Therapeutics, medical director, Khalifa Institute for Personalized Cancer Therapy, professor, breast surgical oncology, The University of Texas MD Anderson Cancer Center in Houston, regular member, Cancer Biology, University of Texas Houston Graduate School of Biomedical Sciences

How a Passion for Translational Research Fuses Surgery, Science, and Phase 1 Drug Development: With D. Ross Camidge, MD, PhD; and Funda Meric-Bernstam, MD

ByRoss Camidge, MD, PhD,Funda Meric-Bernstam, MD

July 8th 2026

This episode highlights Dr Meric-Bernstam's evolution from a science-focused student into a leader in precision oncology and early-phase drug development.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology; MinhTri Nguyen, MD, breast medical oncologist, assistant professor, lead faculty for Health Equity, Rush MD Anderson Cancer Center

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD

BySara Nunnery, MD, MSCI,MinhTri Nguyen, MD

July 7th 2026

Drs Nunnery and Nguyen discuss the emergence of the oral SERD giredestrant in hormone receptor–positive, HER2-negative breast cancer management.

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

July 7th 2026

OncLive On Air® CE

FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD

ByCharles E. Geyer, MD

June 30th 2026

Charles E. Geyer, MD, discusses the FDA approvals of trastuzumab deruxtecan for the management of early-stage HER2-positive breast cancer.

Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

ByClaire Harrison, MD

June 30th 2026

Claire Harrison, MD, discusses data for luspatercept in myelofibrosis-associated anemia from the INDEPENDENCE trial.

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

BySara Nunnery, MD, MSCI,Megan Kruse, MD

June 30th 2026

Drs Nunnery and Kruse discuss the controversy surrounding a biomarker-driven switch strategy in hormone receptor–positive, HER2-negative breast cancer.

Medical Crossfire®: Turning Therapeutic Innovation Into Practice—Personalizing Care in Multiple Myeloma

June 30th 2026

OncLive On Air® CE

Martin Schoen, MD, and Andrew W. Hahn, MD

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

ByMartin W. Schoen, MD, MPH,Andrew W. Hahn, MD

June 30th 2026

Martin Schoen, MD, and Andrew W. Hahn, MD, discuss ARPI use in elderly, frail, and high-comorbidity patients with mCSPC

David O’Malley, MD, The Ohio State University Comprehensive Cancer Center–James

Sequencing and Emerging Targets Revamp the Platinum-Resistant Ovarian Cancer Treatment Paradigm: With David O’Malley, MD

ByDavid O'Malley, MD

June 30th 2026

Dr O’Malley discusses his approach to treatment selection and sequencing in platinum-resistant ovarian cancer.

Unlocking the Power of ctDNA for Residual Disease, Resistance Monitoring, and Real-Time Treatment Decisions in GI Cancers: With Christopher Lieu, MD

ByChristopher Lieu, MD

June 29th 2026

Christopher Lieu, MD, discusses the evolving clinical role of ctDNA in GI oncology, including MRD-guided treatment decisions and liquid biopsy vs tissue testing in mCRC.

FDA Approval Insights: Decitabine/Cedazuridine Plus Venetoclax for AML: With Courtney D. DiNardo, MD, MSCE

ByCourtney DiNardo, MD, MSCE

June 29th 2026

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine and cedazuridine plus venetoclax in acute myeloid leukemia.

Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

June 26th 2026

OncLive On Air® CE

Quadruplet Regimens and T-Cell Redirection Are on the Map of Myeloma Management Strategies: With Chandler Park, MD; Muhamed Baljevic, MD, FACP

ByChandler Park, MD, MSc, FACP,Muhamed Baljevic, MD

June 25th 2026

Drs Park and Baljevic discussed the evolution of myeloma management, including the integration of quadruplet therapies and bispecific antibodies.

D. Ross Camidge, MD, PhD; Mary (Nora) L. Disis, MD

How Strategic Focus Translates to Forward Momentum Across Cancer Immunology Frontiers: With D. Ross Camidge, MD, PhD; and Nora L. Disis, MD

ByRoss Camidge, MD, PhD,Mary L. (Nora) Disis, MD

June 24th 2026

Drs Camidge and Disis discuss Dr Disis’s evolution from a science-focused student to a global leader in cancer immunology.

Noa Biran, MD, breaks down key multiple myeloma data shared at the 2026 ASCO Annual Meeting.

Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD (VIDEO)

ByNoa Biran, MD

June 23rd 2026

Noa Biran, MD, breaks down key multiple myeloma data shared at the 2026 ASCO Annual Meeting.

KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD

ByZev A. Wainberg, MD

June 19th 2026

Zev A. Wainberg, MD, discusses the rapidly evolving landscape of KRAS-directed therapy in PDAC from pan-RAS inhibition to KRAS G12D–specific strategies.

As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD

ByBrad Haverkos, MD

June 18th 2026

Brad Haverkos, MD, discusses evolving management and treatment adherence strategies in cutaneous T-cell lymphoma.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology; Vandana G. Abramson, MD, professor, medicine, co-leader, Breast Cancer Research Program, Breast Cancer Disease Team leader, Vanderbilt Health and the Vanderbilt-Ingram Cancer Center

Oral SERDs Transform Metastatic Breast Cancer Management: With Sara Nunnery, MD, MSCI; and Vandana G. Abramson, MD

BySara Nunnery, MD, MSCI,Vandana G. Abramson, MD

June 16th 2026

Nunnery and Abramson discussed the transformative effects of next-generation oral SERDs in hormone receptor–positive breast cancer management.

Oncology Town Hall: Updates From Berlin: Oral SERDs in HR+/HER2– Metastatic Breast Cancer — What the Latest Data Really Tell Us

June 15th 2026

OncLive On Air® CE

ADCs, Metabolic Health Strategies, and Lifestyle Interventions Add up to Holistic TNBC Care: With Chandler Park, MD; and Neil M. Iyengar, MD

ByChandler Park, MD, MSc, FACP,Neil Iyengar, MD

June 12th 2026

Drs Park and Iyengar discuss the evolving treatment paradigm for TNBC, the integration of metabolic health strategies, and the clinical emergence of ADCs.

Erin Schenk, MD, PhD; D. Ross Camidge, MD, PhD

How Curiosity and Empathy Build a Life of Meaningful Accomplishments and Deep Connections: With Erin Schenk, MD, PhD; and D. Ross Camidge, MD, PhD

ByRoss Camidge, MD, PhD,Erin Schenk, MD, PhD

June 10th 2026

Drs Schenk and Camidge discuss Dr Camidge's storied career and life, which was driven by relentless curiosity and a desire to form meaningful connections.

Joshua Richter, MD, previews some of the most anticipated multiple myeloma presentations ahead of the 2026 EHA Congress.

Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD

ByJoshua Richter, MD

June 10th 2026

Joshua Richter, MD, previews some of the most anticipated multiple myeloma presentations ahead of the 2026 EHA Congress.

ASCO 2026 Plenary: RASolute 302

BySamantha A. Armstrong, MD,Karine Tawagi, MD

June 8th 2026

Two Onc Docs provides a review of data from RASolute 302 of daraxonrasib for the second-line treatment of metastatic pancreatic adenocarcinoma.

Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy

June 5th 2026

The experts unpack molecular profiling for adult and pediatric low- and high-grade gliomas, including a discussion of targeted therapies for MAPK pathway, IDH, and H3K27M altered disease.

Hirsch Matani, MD, Elizabeth Zhang-Velten, MD, PhD, and Binh T. Ngo, MD, discuss radiation and multidisciplinary approaches in skin cancer.

Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD

ByHirsch Matani, MD,Elizabeth Zhang-Velten, MD, PhD,Binh T. Ngo, MD

June 1st 2026

Hirsch Matani, MD, Elizabeth Zhang-Velten, MD, PhD, and Binh T. Ngo, MD, discuss radiation and multidisciplinary approaches in skin cancer.

Archana Jadhav, MD; Monica Peravali, MD; and Anthony Chi, MD; faculty at the Mid-Atlantic Permanente Medical Group

In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD

ByMonica Peravali, MD,Archana Jadhav, MD,Anthony Chi, MD

May 28th 2026

Drs Chi, Peravali, and Jadhav discuss the practical advantages and clinical implications of implementing in-house NGS testing for patients with NSCLC.

Ursula A. Matulonis, MD, chief, Division of Gynecologic Oncology, Brock-Wilson Family Chair, Dana-Farber Cancer Institute, professor, medicine, Harvard Medical School; Meghan E. Shea, MD, attending medical oncologist, ambulatory medical director, disease program leader for medical oncology, Beth Israel Deaconess Medical Center

Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD

ByUrsula A. Matulonis, MD,Meghan E. Shea, MD

May 27th 2026

Drs Matulonis and Shea explore the current landscape of cervical cancer, from the urgent need for expanded vaccination and screening to the evolving role of immunotherapy and ADCs across disease settings.

D. Ross Camidge, MD, PhD; Karen L. Reckamp, MD, director, Medical Oncology, associate director, Clinical Research, medical oncology director, Lung Institute, Cedars Sinai

How Cancer Caregiving Shifts Perspectives in Oncology Practice: With D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD

ByRoss Camidge, MD, PhD,Karen Reckamp, MD

May 27th 2026

Drs Camidge and Reckamp discuss Dr Reckamp's journey as an oncology specialist and now a caregiver for her husband, who has cancer.

Jacob Sands, MD, associate chief of the Lowe Center for Thoracic Oncology, Oncology Medical Director of the International Patient Center, and physician at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School

Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

ByJacob Sands, MD

May 26th 2026

Dr Sands discusses the rapidly evolving treatment landscape for SCLC.

Podcasts

Recent Episodes

All series

Oncology Unplugged With Dr Chandler Park

Pediatrics

Breast Cancer Briefing

Marvels in Medicine

Talking Tumors

Biomarker Consortium

State of the Science Summits

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

OncLive on Air Powered by PER

Roundtable Discussions

Fellowship

Disparities

Rare Cancers

Women In Oncology

Conference Perspectives

OncClub

Oncology Expert Insights

FDA Approval Insights

Blood Club

Two Onc Docs

Cancer, Character, and Calling

How This Is Building Me

All Podcasts

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

How a Passion for Translational Research Fuses Surgery, Science, and Phase 1 Drug Development: With D. Ross Camidge, MD, PhD; and Funda Meric-Bernstam, MD

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD

Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

Medical Crossfire®: Turning Therapeutic Innovation Into Practice—Personalizing Care in Multiple Myeloma

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

Sequencing and Emerging Targets Revamp the Platinum-Resistant Ovarian Cancer Treatment Paradigm: With David O’Malley, MD

Unlocking the Power of ctDNA for Residual Disease, Resistance Monitoring, and Real-Time Treatment Decisions in GI Cancers: With Christopher Lieu, MD

FDA Approval Insights: Decitabine/Cedazuridine Plus Venetoclax for AML: With Courtney D. DiNardo, MD, MSCE

Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

Quadruplet Regimens and T-Cell Redirection Are on the Map of Myeloma Management Strategies: With Chandler Park, MD; Muhamed Baljevic, MD, FACP

How Strategic Focus Translates to Forward Momentum Across Cancer Immunology Frontiers: With D. Ross Camidge, MD, PhD; and Nora L. Disis, MD

Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD (VIDEO)

KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD

As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD

Oral SERDs Transform Metastatic Breast Cancer Management: With Sara Nunnery, MD, MSCI; and Vandana G. Abramson, MD

Oncology Town Hall: Updates From Berlin: Oral SERDs in HR+/HER2– Metastatic Breast Cancer — What the Latest Data Really Tell Us

ADCs, Metabolic Health Strategies, and Lifestyle Interventions Add up to Holistic TNBC Care: With Chandler Park, MD; and Neil M. Iyengar, MD

How Curiosity and Empathy Build a Life of Meaningful Accomplishments and Deep Connections: With Erin Schenk, MD, PhD; and D. Ross Camidge, MD, PhD

Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD

ASCO 2026 Plenary: RASolute 302

Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy

Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD

In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD

Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD

How Cancer Caregiving Shifts Perspectives in Oncology Practice: With D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD

Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

Trending on OncLive

Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued

CD24 Expression Confers Resistance to Anti–PD-1 Therapy in NSCLC, RET-TKI Dose Reductions Do Not Compromise Outcomes in RET+ Disease

FDA Advisory Committee to Review Premarket Approval Application for Multi-Cancer Early Detection Test

Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer

T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer